Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Yervoy (ipilimumab) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. (PubMed, J Clin Oncol) - Sep 10, 2026 - No abstract available
Clinical data • Journal • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Solid Tumor

http://www.ncbi.nlm.nih.gov/pubmed/42715515

Aaron S Mansfield; Adam Lee; Andres Felipe Cardona; Anna K Nowak; Anne S Tsao; Arnaud Scherpereel; Dariusz Kowalski; Francesco Grossi; Gérard Zalcman; Muhammet A Kaplan; Nan Hu; Nobukazu Fujimoto; Paul Baas; Raheela Soomro; Sanjay Popat; Solange Peters; Toby Talbot; Virginia Ip; Yolanda Bautista Aragon; Yu-Han Hung

Sep 10, 2026